Paradigm Biocapital Advisors LP Crinetics Pharmaceuticals, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.67 Billion
- Q1 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 3,124,749 shares of CRNX stock, worth $140 Million. This represents 5.49% of its overall portfolio holdings.
Number of Shares
3,124,749
Previous 2,312,919
35.1%
Holding current value
$140 Million
Previous $82.3 Million
77.74%
% of portfolio
5.49%
Previous 4.27%
Shares
7 transactions
Others Institutions Holding CRNX
# of Institutions
220Shares Held
75.8MCall Options Held
631KPut Options Held
749K-
Black Rock Inc. New York, NY5.44MShares$244 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.23MShares$235 Million2.68% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.95MShares$222 Million0.59% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA4.16MShares$186 Million5.55% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.82MShares$172 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.41B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...